ABBV-8736

Phase 1Small molecule

AbbVie

ABBV-8736 is one of 3 small molecule programs targeting Adverse Events. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Adverse EventsActive, not recruiting

Adverse EventsPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Adverse Events

#DrugCompanyPhaseTrials

ABBV-142

AbbVie

Phase 1

1 2

ABBV-8736

AbbVie

Phase 1

1 3

Glifage

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Rheumatoid Arthritis

NCT06972446

Q1 2030

Phase 2Recruiting

Crohn's Disease

NCT06548542

Clinical

Trials by Indication[1]

Adverse Events1 trial

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

Active, not recruiting· AbbVie logo

AbbVie·Phase 1·NCT07141199·24 enrolled

Rheumatoid Arthritis1 trial

A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06972446·180 enrolled

Crohn's Disease1 trial

A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06548542·590 enrolled

Unspecified1 trial

A Phase 1 Pharmacokinetic Study in Healthy Adult Volunteers to Evaluate the Bioavailability of ABBV-8736 Following Subcutaneous Administration Relative to Intravenous Administration

Completed· AbbVie logo

AbbVie·Phase 1·NCT07413133·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ABBV-8736. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABBV-8736 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABBV-8736. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AbbVie

ABBV-8736

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2030

Trials by Indication[1]

Adverse Events1 trial

Rheumatoid Arthritis1 trial

Crohn's Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News